Drug intelligence / Profile preview

LR 06B

Development stage: Unknown
Lead developer: Laevoroc Oncology
Modality: Small Molecules

Overview

LR 06B is a small molecule drug initially developed by Laevoroc Oncology AG. It is being investigated primarily in the therapeutic areas of neoplasms (cancers), digestive system disorders, and endocrinology and metabolic diseases. Specific inactive indications include breast cancer, ovarian cancer, and pancreatic cancer. The precise mechanism of action, molecular target(s), and detailed pharmacological profile have not been disclosed in public sources as of the latest available data. There are no reported clinical trials or regulatory approvals for this compound to date[1][3].

Targets

DNA polymerase familyRNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on LR 06B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LR 06B.

Explore the full profile